SBRT outcomes for primary and metastatic liver lesions. Background: A479 is an investigational, fully human monoclonal antibody against IGF1R. In a phase II study, 125 pts with mPC were randomized 1:1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results